Startup Creates Brainless Organ Systems to End Animal Testing
Boston, Tuesday, 24 March 2026.
Bay Area biotech R3 Bio is engineering complete organ systems without brains to replace laboratory animals in pharmaceutical testing. The billionaire-backed company plans to create monkey organ ‘sacks’ first, then human versions for drug development. With over 60,000 primates used annually in US research and China’s 2020 export ban creating supply shortages, R3 Bio’s technology could revolutionize medical testing while addressing ethical concerns about animal experimentation.
Breakthrough Biotechnology Innovation
This represents a significant advancement in biotechnology and healthtech, specifically addressing one of the most contentious issues in pharmaceutical research: animal testing. R3 Bio’s approach involves creating genetically-engineered whole organ systems that contain all typical organs except a brain, rendering them unable to think or feel pain [1]. The technology utilizes stem-cell technology and gene editing to develop these organ systems, which the company terms ‘organ sacks’ [1]. Alice Gilman, cofounder of R3 Bio, explains that ‘the benefit of using models that are more ethical and are exclusively organ systems would be that testing can be meaningfully more scalable’ [1].
How the Technology Functions
The innovation works by engineering complete biological systems that maintain all organ functions necessary for pharmaceutical testing while eliminating the capacity for consciousness or pain sensation. R3 Bio is currently working with monkey cells as their initial approach [1]. The company is actively seeking a veterinarian in Puerto Rico to ‘implant embryos, monitor pregnancies and help deliver healthy births’ in nonhuman primates, indicating their immediate focus on creating monkey organ sacks for drug toxicity testing [1]. Stanford University bioethicist Hank Greely supports the ethical framework, stating: ‘If you make a living entity without a brain at all, I think we’d be pretty comfortable with thinking it can’t feel pain’ [1].
Company Leadership and Financial Backing
R3 Bio is based in the Bay Area and co-founded by Alice Gilman, who has been vocal about the company’s mission to revolutionize pharmaceutical testing [1]. The startup has secured backing from several prominent investors, including Immortal Dragons, billionaire venture capitalist Tim Draper, and LongGame Ventures in the UK [1]. Tim Draper expressed his optimism for the venture, stating: ‘We are all better off than we were 150 years ago, and because of forward-thinking entrepreneurs, we will be a lot better off 150 years from now’ [1]. Boyang Wang, CEO of investor Immortal Dragons, has articulated the broader vision: ‘If we can create a nonsentient, headless bodyoid for a human being, that will be a great source of organs’ [1].
Market Context and Future Implications
The timing of R3 Bio’s innovation coincides with significant challenges in the animal testing industry. As of fiscal year 2024, US research facilities reported using over 60,000 nonhuman primates for testing and experimentation [1]. The situation has been exacerbated by China’s 2020 ban on the export of nonhuman primates, which contributed to a dwindling supply of research monkeys in the United States [1]. Additionally, as of January 23, 2026, one of the seven federally funded primate research facilities is considering shutting down, while the US Centers for Disease Control and Prevention is reducing monkey research [1]. The long-term vision extends beyond replacing animal testing, with R3 Bio’s ultimate goal being to create human versions of organ sacks for tissue and organ replacement, potentially revolutionizing both pharmaceutical testing and transplant medicine [1]. However, bioethicist Hank Greely maintains realistic expectations, noting: ‘It’s highly possible that none of this will ever work, but it’s also possible that it could’ [1].